AT-367(AT-367) - 在研适应症：糖尿病_专利_临床

概要

基本信息

药物类型

重组多肽

别名

Implantable insulin pump、AT 367、AT367

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

糖尿病

非在研适应症-

原研机构

Arecor Therapeutics Plc

在研机构

Arecor Therapeutics Plc

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 AT-367 相关的临床结果

登录后查看更多信息

100 项与 AT-367 相关的转化医学

登录后查看更多信息

100 项与 AT-367 相关的专利（医药）

登录后查看更多信息

70

项与 AT-367 相关的文献（医药）

2024-03-01·Indian journal of endocrinology and metabolism

Type 1 Diabetes in Singapore: Self-Care Challenges, Diabetes Technology Awareness, Current Use, and Satisfaction, an Online Survey

Article

作者: Gardner, Daphne ; Ho, Cindy ; Chandran, Suresh Rama ; Yeoh, Ester

Abstract:

Introduction::

To describe the self-care challenges, diabetes technology awareness, current use, and satisfaction among adults with type 1 diabetes and parents of children with type 1 diabetes in Singapore.

Methods::

An anonymous online survey was administered between November 2020 and October 2021. Data are presented as mean (standard deviation) or count (percentages). Comparisons between groups were done using the independent samples T-test.

Results::

251 people (176 adults, 75 parents) participated. The most challenging self-care burdens were carbohydrate counting (24.4%) among adults and insulin dose calculations (28%) among parents. Nocturnal awakenings for diabetes care of their child were a common event (25.3%). Despite high awareness about continuous glucose monitoring devices (77.8% adults, 78.7% parents) the use (24.9% adults, 55% children) remained low. Both adults and parents of children with type 1 diabetes found continuous glucose monitoring to be liberating and less restrictive. Despite overall low insulin pump use (23.9% adults, 29.3% children); satisfaction scores were higher among insulin pump users than insulin pen users (P = 0.02).

Conclusion::

Carbohydrate counting and insulin dose calculations were the most challenging self-care tasks among people with type 1 diabetes in Singapore. Diabetes technology use was relatively low in Singapore. Continuous glucose monitoring and Insulin pump users found them to be beneficial.

2024-03-01·Journal of diabetes science and technology

The Effectiveness of Superbolus on Postprandial Blood Glucose Management of Pregnant Women With Type 1 Diabetes

Article

作者: Pani, Arianna ; Di Vieste, Giacoma ; Bertuzzi, Federico ; Gironi, Ilaria ; Mion, Elena ; Bonomo, Matteo ; Pintaudi, Basilio ; Meneghini, Elena ; Disoteo, Olga

Aim::

Pregnancies of women with pregestational diabetes are at risk of after-meal glucose peaks and late after-meal hypoglycemia, particularly at breakfast. We aimed to explore the effectiveness of a specific feature of insulin pump therapy called superbolus in preventing these glucose swings.

Methods::

In this retrospective observational study, we analyzed continuous glucose monitoring data of patients with type 1 diabetes in pregnancy who were advised to use superbolus to manage their breakfast. Some of the postprandial basal insulin delivery was partially reduced and delivered instead as additional insulin bolus on top of a normal bolus. Outcomes of interest were one hour after breakfast glucose levels, the time in glucose range for after breakfast period, the number of late hypoglycemic episodes.

Results::

Overall, 21 consecutive pregnant women with type 1 diabetes (mean age 34.3 ± 5.5 years, mean pregestational body mass index 23.7 ± 4.7 kg/m2, HbA1c levels during pregnancy 6.1 ± 0.6%) were studied. Superbolus reduced after breakfast glucose peaks (one hour after breakfast glucose levels 130 ± 17 mg/dL vs 123 ± 10 mg/dL before and after superbolus use, respectively, P = .01), improved the time in glucose range for after breakfast period (70.4% vs 50.8%, P = .001), and reduced the number of late hypoglycemic episodes (3 [1-5] vs 1 [0-2], P< .0001).

Conclusion::

Superbolus was effective in avoiding after-meal glucose peaks, increased postprandial glucose time in target, without late hypoglycemia occurrence. It represents a valid option for the treatment of pregnant women with type 1 diabetes using insulin pump.

2024-03-01·Journal of the American Pharmacists Association : JAPhA

Using insulin pump for glycemic control in patients with severe insulin resistance

Article

作者: Burns, Dana ; Allegra, Anthony Garrett ; Sisson, Evan ; Procaccini, Maria

BACKGROUND:

Patients with type 2 diabetes using a continuous subcutaneous insulin infusion (CSII) often require large doses of insulin and need to change their insulin administration sets frequently. A proposed solution to this problem is to use concentrated insulin in their insulin pump; however, insulin pumps are programmed to administer U-100 insulin. Therefore, these patients are at greater risk of hypoglycemia and are responsible for adjusting daily doses.

CASE SUMMARY:

The solution for our patient encountering this problem was to administer half of his daily basal insulin via subcutaneous injection and allow the CSII to administer the remainder through automated insulin delivery (AID). When this strategy was initiated, the patient's A1C was > 14%. After 5 months of follow-up, the patient's A1C was 8.3% and he reported improved quality of life.

PRACTICE IMPLICATIONS:

This technique allows patients with high insulin requirements to benefit from AID without the safety risks associated with using concentrated insulin.

100 项与 AT-367 相关的药物交易

登录后查看更多信息